terazosin / Generic mfg. - LARVOL DELTA

A Green GLANCE-Assisted Spectrofluorimetric Method for the Nanogram-Level Quantification of Terazosin, Singly and in Combination With Triamterene, With Therapeutic Drug Monitoring Applications: Greenness, Whiteness, and Blueness Assessment. (PubMed, Luminescence) - "Statistical analysis showed close agreement between the performance of the proposed and comparison approaches. Greenness, whiteness, and blueness were evaluated for both proposed procedures."

Journal • Cardiovascular • Hypertension

Synergistic Effects of Compound Dendrobium Candidum and Antihypertensive Medications on Refractory Hypertension in Spontaneously Hypertensive Rats. (PubMed, Cardiol Res Pract) - "SHRs were treated with either CDC alone or CDC combined with two or three antihypertensive agents including irbesartan, amlodipine, or terazosin, for a duration of 6 weeks. The mechanism of action may be related to the attenuation of excessive expression of AT2R. This study offers a novel approach for the treatment of clinically resistant hypertension."

Journal • Preclinical • Cardiovascular • Hypertension • IR

Title: Effects of tamsulosin 0.2mg or terazosin 5mg administration on post micturition dribbling (PMD) in men with lower urinary tract symptoms: A Prospective, open-label, Efficacy-evaluation Study (AUA 2026) - No abstract available

Clinical

TZ-DLB: Terazosin for Dementia With Lewy Bodies (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Qiang Zhang | Trial completion date: Dec 2028 ➔ Dec 2030 | Trial primary completion date: Oct 2028 ➔ Oct 2030

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease

Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder. (PubMed, J Clin Psychopharmacol) - "When available and clinically tolerated, prazosin continues to have the best evidence base for use in PTSD-related nightmares. When prazosin use is not feasible, alternative alpha-1 blockers may be effective in a subset of patients."

Journal • Alzheimer's Disease • Behavior Disorders • CNS Disorders • Cognitive Disorders • Depression • Insomnia • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder • Substance Abuse

TAME-PD:: Terazosin And Metabolic Energetics in Parkinson's Disease (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Nandakumar Narayanan

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study. (PubMed, Lancet Digit Health) - "To our knowledge, this analysis is the largest EHR-based study for identifying drug repurposing candidates for ALS. We identified several drugs that warrant further assessment as therapeutic options in ALS, as well as a protein network complex that might serve as a therapeutic target for ALS."

Journal • Retrospective data • Amyotrophic Lateral Sclerosis • CNS Disorders

TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: University of Iowa | N=15 ➔ 20 | Trial completion date: Dec 2026 ➔ May 2027 | Initiation date: Jan 2026 ➔ May 2026 | Trial primary completion date: Jul 2026 ➔ May 2027

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

Terazosin and Parkinson's Disease Extension Study (clinicaltrials.gov) - P2 | N=15 | Active, not recruiting | Sponsor: Cedars-Sinai Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Mar 2026 | Trial primary completion date: Nov 2025 ➔ Mar 2026

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (clinicaltrials.gov) - P2 | N=15 | Active, not recruiting | Sponsor: Cedars-Sinai Medical Center | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

What is the Cost of Selectivity? Selective and Nonselective Alpha Blockade Costs Associated with Adrenalectomy for Pheochromocytoma. (PubMed, Ann Surg Oncol) - "When compared with nonselective alpha blockers, selective alpha blockers are associated with lower medication costs but equivalent hospitalization and post-hospitalization costs."

Journal • Critical care • Oncology • Solid Tumor

Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis. (PubMed, Int Neurourol J) - "This study found no significant association between the use of alpha-blockers or 5ARIs and increased dementia risk. These findings may assist clinicians in making more informed prescribing decisions, particularly for older male patients with BPH. Further large-scale research with extended follow-up periods is needed to strengthen the evidence across all BPH medications."

Journal • Retrospective data • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia

Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025. (PubMed, Arab J Urol) - "Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones."

Journal • Retrospective data • Review • Pain • Renal Calculi • Urolithiasis

APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice. (PubMed, Neurobiol Dis) - "Together, these findings suggest that reductions in hippocampal expression of sodium/potassium-ATPase and glycolytic enzymes may underlie APOE4-associated hippocampal hyperexcitability, revealing a novel mechanistic insight. Our results also demonstrate potent anti-seizure effects of terazosin, supporting the possibility of repurposing this anti-hypertension drug to mitigate seizure comorbidity in AD."

Journal • Preclinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Epilepsy • Hypertension • PGK1 • PKM

TAME-PD: Terazosin And Metabolic Engagement in Parkinson's Disease (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Nandakumar Narayanan

New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: University of Iowa | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

GLANCE-aided snapshotting for sustainable integration of synchronous spectrofluorimetry and micellar boosting for nanoscale assay of tolterodine binary mixtures in crucial matrices. (PubMed, Sci Rep) - "Tolterodine tartrate (TLD) has recently demonstrated remarkable synergism when combined with either of two α1-adrenergic antagonists, doxazosin mesilate (DXZ) or terazosin hydrochloride dihydrate (TRZ), for treating urinary tract issues. The outcomes demonstrated the excellence of the designed methodology over reported approaches, offering proficient sensitivity, sustainability, facility, and practicability across diverse crucial matrices. These findings provide compelling evidence that the proposed work serves as an efficient, eco-friendly quantification tool for use in quality control, biological, and environmental sectors, fostering a more eco-conscious and sustainable scientific community."

Journal

Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer's Disease. (PubMed, J Med Chem) - "Virtual screening of FDA-approved drugs prioritized nilotinib, a BCR-ABL inhibitor, as a putative PPI disruptor...Guided by these findings, we developed a lysate-based TR-FRET ultrahigh-throughput assay that identified additional inhibitors, including α1-adrenergic antagonists doxazosin, terazosin, and alfuzosin. These compounds suppressed cytokine induction via docking groove blockade. Together, these results establish a non-ATP-competitive approach for selectively targeting the p38/MK2 complex and highlight the translational potential of drug repurposing to modulate neuroinflammation in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • ABL1 • BCR

APOE4 Reduces Glycolytic Enzymes and Sodium Potassium Pump to Enhance Seizure Susceptibility (AES 2025) - "A subset of APOE4 and APOE4/PS19 mice were treated with terazosin (1 mg/kg) with/out sodium oxamate (1 g/kg) prior to KA injections... APOE4 induced an age-dependent increase in seizure susceptibility, along with reduced hippocampal expression of Na⁺/K⁺-ATPase and glycolytic enzymes, as well as decreased ATP levels. These findings suggest that disruption of the electrochemical gradient and impaired ATP production contribute to the APOE4-associated rise in seizure susceptibility."

Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Dementia • Epilepsy • APOE

Not Just One Answer: A Case of Resistant Hypertension with Overlapping Etiologies (KIDNEY WEEK 2025) - "Despite adherence to a low sodium diet, CPAP and a six-drug regimen including amlodipine 10mg, metoprolol 150mg, lisinopril 40mg, terazosin 20mg, chlorthalidone 25mg, and spironolactone 25mg daily, BP remained elevated at 160-180/80-90 mm Hg...He remained on metoprolol ER 50mg, diltiazem 240mg, furosemide 20mg daily for his hypertrophic cardiomyopathy...A concurrent renal artery stenosis was managed with angioplasty that helped bring his BP to goal. With this case, we highlight the importance of identifying and understanding the pathophysiology of secondary causes of resistant hypertension."

Clinical • Cardiomyopathy • Cardiovascular • Endocrine Disorders • Hypertension • Hypertrophic Cardiomyopathy • Nephrology • Renal Calculi

Pgk1 activation restores endothelial metabolic homeostasis to alleviate vascular aging and atherosclerosis. (PubMed, Cardiovasc Diabetol) - "Terazosin (TZ), a well-known antagonist of the α1-adrenergic receptor (α1-AR), has demonstrated protective effects on vascular endothelial cells (ECs) and reduced vascular stiffness in clinical studies...TZ effectively reversed these changes. Overall, our study demonstrates that TZ primarily alleviates EC senescence and atherosclerosis through the Pgk1/Hsp90/Prdx1 pathway, highlighting Pgk1 activation as a strategy that may also mitigate endothelial dysfunction and oxidative stress in broader cardiometabolic contexts (e.g., diabetes), suggesting that TZ is a promising senomorphic agent for treating vascular aging and atherosclerosis in clinical settings and that Pgk1-targeted interventions could have implications beyond atherosclerosis."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Metabolic Disorders • APOE • CDC37 • HSP90AA1 • PGK1 • PRDX1

TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: University of Iowa

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity."

Journal • Cardiovascular • Hypertension • Hypotension • Myocardial Infarction • Pain